AstraZeneca Analyst Price Targets - Benzinga

AstraZeneca PLC

AZNNYSE

Trade with Public

Trade with Public

$162.47

0.340.21%

近くで: Aug 31, 5:00 PM EST

$160.96

-1.17-0.72%

プレマーケット: 4:44 AM EST

概要ニュース業績予想イベント目標株価財務センチメント株主構成配当比較オプション株式レポート

AstraZeneca Analyst Price Targets

Wall Street analyst price targets and consensus rating for AstraZeneca (AZN).

Price Target Range — 5 Quarters

Analyst Consensus — 10 Analysts

9Buy

1Hold

Consensus RatingBuy# Analysts10Avg. Consensus PT$107Upside to Avg. PT-33.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 24, 2026	CICC	Yuan Guo	Initiate	Outperform	$198
Oct 27, 2025	Jefferies	Michael Leuchten	Assumes	Hold→Buy	—
Feb 13, 2025	UBS	Matthew Weston	Upgrade	Neutral→Buy	—
Nov 20, 2024	UBS	Matthew Weston	Upgrade	Sell→Neutral	—
Sep 11, 2024	Erste Group	Hans Engel	Upgrade	Hold→Buy	—
Aug 12, 2024	TD Cowen	Steve Scala	PT Raise	Buy	$90→$95
May 30, 2024	Argus Research	Jasper Hellweg	PT Raise	Buy	$80→$85
May 30, 2024	Goldman Sachs	Rajan Sharma	Initiate	Buy	$97
Apr 26, 2024	BMO Capital	Etzer Darout	PT Raise	Outperform	$80→$82
Apr 16, 2024	Deutsche Bank	Emmanuel Papada	Upgrade	Sell→Hold	—
Feb 12, 2024	BMO Capital	Etzer Darout	PT Cut	Outperform	$82→$80
Feb 8, 2024	Deutsche Bank	Emmanuel Papadakis	Downgrade	Buy→Hold	—
Jan 23, 2024	Morgan Stanley	Mark Purcell	Initiate	Overweight	$85
Jan 3, 2024	Jefferies	Peter Welford	Downgrade	Buy→Hold	—
Sep 25, 2023	Jefferies	Peter Welford	Upgrade	Hold→Buy	$67→$80
Sep 8, 2023	Erste Group	—	Downgrade	Buy→Hold	—

More with Benzinga EdgeGet Access

Analyst Ratings News

BioMarin Seeks to Strengthen Market Position in Rare Bone Disease Treatment

BioMarin Pharmaceutical agrees to acquire Alesta Therapeutics for $275 million upfront, securing ALE1 for rare bone disease treatment.

Vandana Singh

Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape

Cullinan Therapeutics and Taiho report positive Phase 3 trial results for zipalertinib in treating advanced lung cancer.

Vandana Singh

AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus

AstraZeneca and Bristol Myers reportedly discuss a $400 billion merger as analyst assesses valuation, patent risks and regulatory hurdles.

Vandana Singh

Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain

Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome favors existing and next-gen therapies.

Vandana Singh

March Inflation Set For Biggest Jump Since June 2022 — When CPI Spikes, These Stocks Fall

Trump, in January, said "inflation has been defeated." Wall Street is now bracing for a 0.9% monthly CPI surge — the steepest since June 2022.

Piero Cingari

Royalty Rift: Alexion Cuts Off US Royalty Payments To Xencor

Alexion refuses to pay Xencor for U.S. Ultomiris sales. Read Xencor's response and the new 2028 operating runway details.

Vandana Singh